Yan Valle

Yan Valle

Auto-generated profile, based on publicly available information

Yan Valle

Vitiligo Research Foundation New York New York USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2016 in Nature Genetics
Verified
Journal Article
Open access
PDF file
YJYing Jin
Ying Jin
GAGenevieve Andersen
Genevieve Andersen
DYDaniel Yorgov
Daniel Yorgov
TFTracey M Ferrara
Tracey M Ferrara
SBSongtao Ben
Songtao Ben
RSRichard A. Spritz
Richard A. Spritz
Richard Spritz and colleagues present a genome-wide association study of autoimmune vitiligo in 4,680 cases and 39,586 controls and report 23 new risk loci. Their results highlight specific pathways, including immune response, apoptosis and melanocyte function, that may be important in the pathobiology of autoimmune vitiligo. Vitiligo is an autoimmune disease in which depigmented skin results from the destruction of melanocytes1, with epidemiological association with other autoimmune diseases2. In previous linkage and genome-wide association studies (GWAS1 and GWAS2), we identified 27 vitiligo susceptibility loci in patients of European ancestry. We carried out a third GWAS (GWAS3) in European-ancestry subjects, with augmented GWAS1 and GWAS2 controls, genome-wide imputation, and meta-analysis of all three GWAS, followed by an independent replication. The combined analyses, with 4,680 cases and 39,586 controls, identified 23 new significantly associated loci and 7 suggestive loci. Most encode immune and apoptotic regulators, with some also associated with other autoimmune diseases, as well as several melanocyte regulators. Bioinformatic analyses indicate a predominance of causal regulatory variation, some of which corresponds to expression quantitative trait loci (eQTLs) at these loci. Together, the identified genes provide a framework for the genetic architecture and pathobiology of vitiligo, highlight relationships with other autoimmune diseases and melanoma, and offer potential targets for treatment.

31 December 2019 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
KAKomal Agarwal
Komal Agarwal
IPIndrashis Podder
Indrashis Podder
Martin KassirMartin Kassir
Martin Kassir
AVAleksandra Vojvodic
Aleksandra Vojvodic
Robert A SchwartzRobert A Schwartz
Robert A Schwartz
Mohamad GoldustMohamad Goldust
Mohamad Goldust

21 January 2018 in Open Access Macedonian Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
SGSerena Gianfaldoni
Serena Gianfaldoni
GTGeorgi Tchernev
Georgi Tchernev
UWUwe Wollina
Uwe Wollina
MRMaria Grazia Roccia
Maria Grazia Roccia
MFMassimo Fioranelli
Massimo Fioranelli
TLTorello Lotti
Torello Lotti
BACKGROUND: Vitiligo is an acquired pigmentary cutaneous disease, characterised by the progressive loss of melanocytes, resulting in hypopigmented skin areas which progressively become amelanotic. Classically, vitiligo treatments are unsatisfactory and challenging. Despite the continuous introduction of new therapies, phototherapy is still the mainstay for vitiligo repigmentation.AIM: The aim of this multicenter observational retrospective study was to evaluate the efficacy and safety of the nb - UVB micro - phototherapy (BIOSKIN EVOLUTION®), used alone or in associations with an oral Janus kinase inhibitor (Tofacitinib citrate), in the treatment of stable or active forms of localised vitiligo.MATERIAL AND METHODS: Fifty eight patients had been treated with n-UVB micro-photootherapy (Group A); 9 patients had been treated with phototherapy plus Tofacitinb citrate (Group B).RESULTS: Among Group A, 42 patients (72%) obtained a re-pigmentation rate higher than 75%, with a medium value of 77%. 11 patients (19%) achieved a marked improvement of the clinical findings with a repigmentation rate between 50-75%; 4 patients (8%) showed a moderate response with a lesional repigmentation of 25-50%. Only one patient (1%) had a poor response to the phototherapeutic treatmentCONCLUSION: Nb - UVB micro-focused phototherapy is one of the most effective therapeutic options for vitiligo treatment. The association of micro-focused phototherapy to Tofacitinib citrate seems to provide better clinical results in term of repigmentation rate.

1 November 2012 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
BLBrian W. Lee
Brian W. Lee
RSRobert A. Schwartz
Robert A. Schwartz
JHJana Hercogová
Jana Hercogová
YVYan Valle
Yan Valle
TLTorello M. Lotti
Torello M. Lotti

21 January 2018 in Open Access Macedonian Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
TLTorello Lotti
Torello Lotti
UWUwe Wollina
Uwe Wollina
GTGeorgi Tchernev
Georgi Tchernev
YVYan Valle
Yan Valle
JLJacopo Lotti
Jacopo Lotti
SGSerena Gianfaldoni
Serena Gianfaldoni
Despite the continuous introduction of innovative therapies for vitiligo, today none of them provide constant and excellent results in term of repigmentation. The authors report their experience in treating a localised form of vitiligo with a new protocol consisting in the use of a Fraxel Herbium laser, and in the following application of topical Latanoprost solution and, one day after, in lesional irradiation with UVA1 laser.

1 November 2012 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
TLTorello M. Lotti
Torello M. Lotti
JHJana Tresnak Hercogova
Jana Tresnak Hercogova
RSRobert A. Schwartz
Robert A. Schwartz
DTDionigi Tsampau
Dionigi Tsampau
IKIgor Korobko
Igor Korobko
GBGionata Buggiani
Gionata Buggiani